Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, announces the following Board appointment.
Reflecting his exceptional experience and valued contribution to the progress of OCTP, the Company is pleased to announce the appointment of Dr Tim Corn, Chief Medical Officer ("CMO"), as an executive director, effective immediately. As announced on 8 June 2023, Dr Corn joined OCTP as CMO to oversee the Company's clinical research and development activities as well as to provide expert medical guidance and advice to the team. Since joining, the Company has successfully completed its first Phase I clinical trial, a single ascending dose study of its lead compound OCT461201.
Dr Corn, formerly Chief Medical Officer International at Jazz Pharmaceuticals plc, has played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists.
Read the full story here.
Date posted: 14 November 2023
Article tag: Oxford Cannabinoid Technologies
Share